The FDA announced that ligelizumab has received the Breakthrough Therapy designation for the treatment of chronic spontaneous urticaria for patients who have had an inadequate response to H1-antihistamines.
The FDA approved a new therapy to increase pain-free light exposure in adult patients with a history of phototoxic reactions caused by erythropoietic protoporphyria.